Skip to main content
. Author manuscript; available in PMC: 2021 May 15.
Published in final edited form as: Antiviral Res. 2017 Aug 24;146:139–145. doi: 10.1016/j.antiviral.2017.08.016

Fig. 4. Relative plasma miR-122 levels.

Fig. 4

(4A) Relative plasma miR-122 level at baseline in patients with (black dots) and without (grey dots) previous RG-101 dosing and healthy controls (HC, white triangles), median and interquartile range are shown. Mann-Whitney U test was used to compare study groups. (4B) Relative plasma miR-122 levels in CHC patients with (black dots) and without (grey dots) prior RG-101 dosing treated with SOF + DAC at baseline and follow-up week 12 (FU12). Wilcoxon test was used to compare baseline and FU12. Mann-Whitney U test was used to compare FU12 of different study groups. (4C) Relative plasma miR-122 levels in CHC patient throughout the study period up to FU12, as well as in healthy controls, median and interquartile range are shown. One-way ANOVA was used to compare study groups. **p < 0.01; ***: p < 0.001; ****: p < 0.0001.